Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 28.52B, Biogen(BIIB) trades at $193.17. The stock has a price-to-earnings ratio of 22.43.
On 2026-07-14, Biogen(BIIB) stock traded between a low of $189.40 and a high of $217.00. Shares are currently priced at $193.17, which is +2.0% above the low and -11.0% below the high.
Biogen(BIIB) shares are trading with a volume of 2.74M, against a daily average of 1.4M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
BIIB News
(RTTNews) - Eisai Co Ltd (ESALY.PK) and Biogen Inc. (BIIB) announced on Tuesday new real-world data showing that 82.5 percent of patients with early Alzheimer's...
Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Biogen. The associated price target remains the same with $237.00. TipRanks has ente...
Shares of Biogen BIIB rose nearly 5% yesterday after the company announced that the FDA approved a subcutaneous (SC) autoinjector version of Leqembi as an initi...
Analyst ratings
61%
of 38 ratingsMore BIIB News
Biogen stock was down more than 8% Tuesday—on pace for its largest drop since 2020—after the company's experimental Alzheimer's drug failed to perform better on...
After Biogen (BIIB) provided more detailed data from the Phase 2 CELIA study of diranersen in early Alzheimer’s disease during this morning at AAIC session, RBC...
Following the announcement, the stock fell nearly 9%. According to Bloomberg, RBC Capital Markets analyst Brian Abrahams said the findings “leave more questions...
Eisai (ESAIY) and Biogen (BIIB) announced that results from the real-world Lecanemab in Early Alzheimer’s Disease Study show that nearly 83% of early Alzheimer’...
...
Biogen (CIIB) shares fell in the morning hours on Tuesday after the company announced additional data from a mid-stage trial for diranersen, a novel experimenta...
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antis...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.